Development of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD.

The difference in the number and distribution of lesions in rAAV2/2[MAX]smCBA-Eylea and PBS control groups was highly significant ( p < 0.0001, Chi Square test), strongly indicating that rAAV-mediated over-expression of an anti-VEGF agent is able to prevent disease pathology in AMD (Fig. 5H ).

also in 132,142 other papers